

Supplementary tables to

Long-term relative survival in uveal melanoma: a systematic review and meta-analysis

Gustav Stålhammar M.D. Ph.D.^{1,2} Christina Herrspiegel M.D.^{1,2}

¹St. Erik Eye Hospital, Box 4078, 171 04 Solna, Stockholm, Sweden,

²Department of Clinical Neuroscience, Karolinska Institutet, Tomtebodavägen 18A, plan 5, 171 77 Stockholm, Sweden.

Table of contents:

<i>Page 2</i>	Supplementary table 1. Estimations of relative survival in a Finnish cohort published by Kujala <i>et al.</i>
<i>Page 3</i>	Supplementary table 2. Data collection methods for included studies.
<i>Page 4</i>	Supplementary table 3. Combined estimate of relative survival rates 1 through 30 years after uveal melanoma diagnosis.
<i>Page 5</i>	Supplementary table 4. Estimates of variance of relative survival in included studies.

Year after diagnosis	All-cause mortality	Melanoma-related mortality	Expected survival Swedish reference population	Relative survival	95 % CI upper of observed survival rate	95 % CI lower of observed survival rate	Standard error of observed survival rate	95 % CI upper of relative survival rate	95 % CI lower of relative survival rate	1 minus relative survival
5	0.62	0.69	0.98	0.63	0.68	0.56	0.03	0.66	0.60	0.37
10	0.47	0.60	0.82	0.57	0.52	0.41	0.03	0.61	0.54	0.43
15	0.35	0.55	0.65	0.54	0.40	0.29	0.03	0.58	0.50	0.46
20	0.25	0.52	0.50	0.50	0.30	0.20	0.03	0.55	0.45	0.50
25	0.21	0.51	0.34	0.62	0.26	0.16	0.03	0.69	0.54	0.38
30	0.18	0.50	0.22	0.82	0.22	0.13	0.02	0.92	0.71	0.18

Supplementary table 1. Estimations of relative survival in the Finnish cohort published by Kujala *et al.* (Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44(11):4651-9.)

#	Data collection method	<i>n</i> (%)
1	Population-based registries outside the authors' institution, including cancer registries and cause of death registries	4 (44)
2	Institution's clinical records	0 (0)
3	Combination of 1 and 2	5 (55)
4	Other	0 (0)

Supplementary table 2. Data collection methods for included studies.

Year after diagnosis	Relative survival, %
1	95
2	90
3	86
4	82
5	79
6	76
7	73
8	70
9	68
10	66
11	64
12	63
13	62
14	61
15	60
16	60
17	59
18	59
19	59
20	60
21	60
22	60
23	61
24	62
25	62
26	63
27	64
28	65
29	66
30	67

Supplementary table 3. Combined estimate of relative survival rates 1 through 30 years after uveal melanoma diagnosis.

Variance statistic	5 years	10 years	15 years	20 years	25 years	30 years
Tau ²	0.01	0.01	0.01	0.01	0.01	0.02
Chi ²	241	72	39	13	4	14
I ²	97 %	94 %	92 %	85 %	48 %	86 %

Supplementary table 4. Estimates of variance of relative survival in included studies.